| Rank |
Status |
Study |
| 1 |
Active, not recruiting |
Hematopoietic Stem Cell Transplantation in Myeloma
| Condition: |
Multiple Myeloma |
| Intervention: |
Procedure: Hematopoietic Stem Cell Transplantation |
|
| 2 |
Recruiting |
A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)
| Condition: |
Acute Myelogenous Leukemia |
| Intervention: |
Drug: cytosine arabinoside |
|
| 3 |
Recruiting |
Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients
| Conditions: |
Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia |
| Interventions: |
Procedure: Standard conditioning prior allo SCT; Procedure: Dose-reduced conditioning prior allo SCT |
|
| 4 |
Recruiting |
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
| Condition: |
Cancer |
| Intervention: |
Drug: caspofungin acetate |
|
| 5 |
Completed |
A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia
| Condition: |
Acute Myelogenous Leukemia |
| Intervention: |
Behavioral: Two-step remission induction and risk-oriented consolidation |
|
| 6 |
Recruiting |
Efficacy and Safety of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR™) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
| Conditions: |
Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders |
| Intervention: |
Biological: Donor lymphocyte preparation depleted of functional alloreactive T-cells |
|
| 7 |
Recruiting |
High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk
| Conditions: |
HIV-Related Lymphoma; HIV Infections |
| Intervention: |
Other: Rituximab and CHOP regimen + PBSCT |
|
| 8 |
Recruiting |
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
| Condition: |
Multiple Myeloma |
| Intervention: |
Procedure: Hematopoietic Stem Cell Transplantation |
|
| 9 |
Completed |
Effect of Sitagliptin on Endothelial Progenitor Cells
| Condition: |
Type 2 Diabetes Mellitus |
| Intervention: |
Drug: Sitagliptin |
|
| 10 |
Recruiting |
Bone Marrow Progenitor Cell Mobilization in Diabetes
| Condition: |
Diabetes Mellitus |
| Intervention: |
Drug: Filgrastim, hrG-CSF |
|
| 11 |
Active, not recruiting |
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
| Condition: |
Central Nervous System Lymphoma |
| Interventions: |
Drug: Methotrexate; Drug: Ara-C; Drug: Rituximab; Drug: Thiotepa; Radiation: radiotherapy; Drug: BCNU; Other: APBSCT |
|
| 12 |
Recruiting |
Combination Chemotherapy With or Without Imatinib Mesylate and/or Peripheral Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
| Condition: |
Leukemia |
| Interventions: |
Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: idarubicin; Drug: imatinib mesylate; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: mitoxantrone hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy |
|
| 13 |
Active, not recruiting |
This is a Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM.
| Conditions: |
Lymphoma (Non-Hodgkin's Lymphoma); Hodgkin's Disease or Multiple Myeloma; Front Line Mobilization; Transplantation |
| Intervention: |
Drug: Generic = Plerixafor |
|
| 14 |
Recruiting |
Bronchodilator Responsiveness in Bronchiolitis Obliterative Syndrome (BOS)
| Condition: |
Bronchiolitis Obliterative Syndrome |
| Intervention: |
Drug: albuterol plus tiotropium |
|
| 15 |
Recruiting |
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
| Condition: |
Myelofibrosis |
| Intervention: |
Drug: Fludarabine, Melphalan +/- ATG |
|
| 16 |
Recruiting |
Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
| Condition: |
Leukemia |
| Interventions: |
Biological: alemtuzumab; Biological: filgrastim; Drug: carmustine; Drug: cyclophosphamide; Drug: cytarabine; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: thiotepa; Procedure: autologous hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation |
|
| 17 |
Completed |
Treatment of Adult ALL With an MRD-Directed Programme.
| Condition: |
Acute Lymphoblastic Leukemia |
| Intervention: |
Behavioral: Postremission consolidation based on MRD status |
|
| 18 |
Active, not recruiting |
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
| Condition: |
Cytomegalovirus Infections |
| Interventions: |
Drug: maribavir; Other: placebo |
|
| 19 |
Recruiting |
High-Dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients
| Condition: |
Hodgkin's Lymphoma |
| Intervention: |
Drug: ABVD |
|
| 20 |
Recruiting |
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
| Conditions: |
Diffuse Large B-Cell Lymphoma; IPI≥2 |
| Interventions: |
Drug: Rituximab; Drug: Ciclofosfamide; Drug: Doxorubicina; Drug: Vincristina; Drug: Prednisone; Drug: Pegfilgrastim; Drug: Mitoxantrone; Drug: ARA-C; Drug: Lenograstim; Drug: BCNU; Drug: VP-16; Procedure: ASCT |
|